Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study

Treatment options for previously treated metastatic triple-negative breast cancer (mTNBC) are limited. In cohort A of the phase II KEYNOTE-086 study, we evaluated pembrolizumab as second or later line of treatment for patients with mTNBC. Eligible patients had centrally confirmed mTNBC, ≥1 systemic...

Full description

Saved in:

Bibliographic Details
Published in:	Annals of oncology Vol. 30; no. 3; p. 397
Main Authors:	Adams, S, Schmid, P, Rugo, H S, Winer, E P, Loirat, D, Awada, A, Cescon, D W, Iwata, H, Campone, M, Nanda, R, Hui, R, Curigliano, G, Toppmeyer, D, O'Shaughnessy, J, Loi, S, Paluch-Shimon, S, Tan, A R, Card, D, Zhao, J, Karantza, V, Cortés, J
Format:	Journal Article
Language:	English
Published:	England 01.03.2019
Subjects:	Adult Aged Aged, 80 and over Anthracyclines - administration & dosage Antibodies, Monoclonal, Humanized - administration & dosage Antibodies, Monoclonal, Humanized - adverse effects B7-H1 Antigen - genetics Bridged-Ring Compounds - administration & dosage Cohort Studies Female Gene Expression Regulation, Neoplastic - drug effects Humans Middle Aged Neoplasm Metastasis Progression-Free Survival Taxoids - administration & dosage Triple Negative Breast Neoplasms - drug therapy Triple Negative Breast Neoplasms - genetics Triple Negative Breast Neoplasms - pathology pembrolizumab triple-negative breast neoplasms anti-PD-1 immunotherapy
ISSN:	1569-8041, 1569-8041
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!